eRapport

Myocardial dysfunction in acute COPD

Prosjekt
Prosjektnummer
2014006
Ansvarlig person
Helge Røsjø
Institusjon
Akershus universitetssykehus HF
Prosjektkategori
Doktorgradsstipend
Helsekategori
Cardiovascular
Forskningsaktivitet
4. Detection and Diagnosis
Rapporter
2023 - sluttrapport
Dr. Erika N Aagaard has finalized her thesis by a successful defence in 2023. Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we have utilized both sensitive echocardiographic indices and biological markers (biomarkers) to explore the influence of COPD and other cardiac risk factors more closely. The candidate defended her thesis on the associations between novel echocardiographic indices, especially myocardial dispersion, and common risk factors, including COPD, in 2023. Dr. Aagaard found that common cardiovascular risk factors mainly explain increased myocardial dispersion, which is heterogeneous contraction of the left ventricle. In contrast, the influence of self-reported or adjudicated diagnosis of COPD did not influence myocardial dysfunction in multivariable analysis. Dr. Aagaard also reported reference values for myocardial dispersion, which has gained significant interest as reference values are needed, also to diagnose heterogenous myocardial contraction in COPD patients. Hence, we find that common risk factors like smoking may cause myocardial dysfunction in COPD patients, but mainly through the effect of established cardiovascular disease or other cardiovascular risk factors. We have used non-HSØ funding to finalize this work in 2023. We are also performing a second, follow-up study related to this work (ACE 4 Study; NCT05699564, https://clinicaltrials.gov/study/NCT05699564?locStr=Norway&country=Norway&term=ace%204%20study&rank=1), which will expand our knowledge of the impact of COPD in patients hospitalized with acute dyspnea. The ACE 4 Study has included >400 patients and will be finalized in Q2 2024 with aim of 600 patients. There is a need to early identify subtle changes in myocardial function, both for COPD patients and other patients. Dr. Aagaard has used both established and novel echocardiographic indices and report important information related to especially the novel marker myocardial dispersion. Dr. Aagaard did not find significant interaction between COPD and myocardial dispersion in her work, but we will continue this work also in a large cohort of patients hospitalized with acute dyspnea (ACE 4 Study; NCT05699564, https://clinicaltrials.gov/study/NCT05699564?locStr=Norway&country=Norway&term=ace%204%20study&rank=1). Dr. Aagaard has defended her thesis and her work received strong support by the external opponents, who are international leaders in the field. Accordingly, Dr. Aagaard has contributed successfully to advancing our understanding and ability to detect early, subtle changes in myocardial function, both for COPD patients and other patients.

No

2022
Patients with chronic obstructive pulmonary disease (COPD) have comorbidities, including myocardial dysfunction. This may relate both to common risk factors, but also to direct effects by COPD and other risk factors on the myocardium. We have utilized sensitive echocardiographic and biological markers to explore this and related research questions.Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we have utilized both sensitive echocardiographic indices and biological markers (biomarkers) to explore the influence of COPD and other cardiac risk factors more closely. We have included the cohorts of interest and have extensive pulmonary testing and echocardiographic examinations in all subjects in the main cohort of the thesis of the candidate. The candidate published her third article on the associations between novel echocardiographic indices and common risk factors, including COPD, in 2022. We find that cardiovascular risk factors mainly explain increased myocardial dispersion, which is heterogeneous contraction of the left ventricle. In contrast, the influence of self-reported or adjudicated diagnosis of COPD did not influence myocardial dysfunction in multivariable analysis. Hence, we find that common risk factors like smoking may cause myocardial dysfunction in COPD patients, but mainly through the effect of established cardiovascular disease or other cardiovascular risk factors. We have used non-HSØ funding to finalize this work in 2022 and the candidate submitted the PhD thesis to the University of Oslo in January 2023. Assessment of the thesis and the public defense are expected during Q2-3 2023.

Nei

2021
Patients with chronic obstructive pulmonary disease (COPD) often have comorbidities, including myocardial dysfunction. We have utilized sensitive echocardiographic and biological markers to explore the associations between these markers, and also the correlation with risk factors such as COPD.Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we have utilized both sensitive echocardiographic indices and biological markers (biomarkers) to explore this research question more closely. We have included the cohorts of interest and have extensive pulmonary testing and echocardiographic examinations in all subjects in the main cohort of the thesis of the candidate. We have published two articles on the associations between novel echocardiographic indices and common risk factors, including COPD, and the third article was recently accepted. We find that cardiovascular risk factors mainly explain increased myocardial dispersion, which is heterogeneous contraction of the left ventricle. In contrast, the influence of self-reported or adjudicated diagnosis of COPD did not influence myocardial dysfunction in multivariable analysis. Hence, we find that common risk factors like smoking may cause myocardial dysfunction in COPD patients, but mainly through the effect of established cardiovascular disease or other cardiovascular risk factors. The candidate will use non-HSØ funding to finalize the doctoral thesis and the candidate should be able to submit the thesis during 2022. The PhD candidate has completed all mandatory courses at the University of Oslo for the degree of Ph.D. The candidate has also contributed as a co-author on 5 other publications during the funding period from HSØ.

NEI

2020
Patients with chronic obstructive pulmonary disease (COPD) often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors, but also to direct effects by COPD and other risk factors on the myocardium. We have utilized both sensitive echocardiographic and biological markers to explore this research question.The project has not been finalized in 2020 due to lack of dedicated research time for the PhD candidate and high clinical load on the candidate due to Covid-19 (work in the Medical Intensive Care Unit). The main results have previously been reported and we find that cardiovascular risk factors explain increased myocardial dispersion, which is heterogeneous contraction of the left ventricle and a sensitive marker of myocardial dysfunction. In contrast, the influence of self-reported or adjudicated diagnosis of COPD did not influence myocardial dysfunction in multivariable analysis. Hence, we find that common risk factors like smoking may cause myocardial dysfunction in COPD patients, but mainly through the effect of established cardiovascular disease or other cardiovascular risk factors. This has already been reported in one published article and we have a second article with the candidate as primary author soon ready to be submitted. The candidate has also started on the thesis and we will aim to finalize this project in 2021 with the candidate defending her PhD at the University of Oslo. The candidate has completed all mandatory courses at the University of Oslo for the degree of Ph.D. The candidate is also co-author on 4 other publications based on her work during the funding period from HSØ.

NEI

2019
Patients with chronic obstructive pulmonary disease (COPD) often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors, but also to direct effects by COPD and other risk factors on the myocardium. We have utilized both sensitive echocardiographic and biological markers to explore this research question.Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we have utilized both sensitive echocardiographic indices and biological markers (biomarkers) to explore this research question more closely. We have included the cohorts of interest and have extensive pulmonary testing and echocardiographic examinations in all subjects in the main cohort of the thesis of the candidate. We have published two articles on the associations between novel echocardiographic indices and common risk factors, including COPD. We find that cardiovascular risk factors mainly explain increased myocardial dispersion, which is heterogeneous contraction of the left ventricle. In contrast, the influence of self-reported or adjudicated diagnosis of COPD did not influence myocardial dysfunction in multivariable analysis. Hence, we find that common risk factors like smoking may cause myocardial dysfunction in COPD patients, but mainly through the effect of established cardiovascular disease or other cardiovascular risk factors (reported article and one article that was published now in 2020, but accepted in 2019). We also have a third article in progress, but this work is still to be completed due to acute illness in the project group. We will use non-HSØ funding to finalize this work in 2020 and the candidate should be able to submit the thesis in 2020. The PhD candidate has completed all mandatory courses at the University of Oslo for the degree of Ph.D. The candidate has also contributed as a co-author on 3 other publications during the funding period from HSØ.

NEI

2018
Patients with chronic obstructive pulmonary disease (COPD) often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors, but also to direct effects by COPD and other risk factors on the myocardium. We will utilize both sensitive echocardiographic and biological markers to explore this research question.Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we will utilize both sensitive echocardiographic indices and biological markers (biomarkers) to explore this research question more closely. We have included the cohorts of interest with pulmonary testing and echocardiographic examinations in all subjects. We have also completed measurements of high-sensitivity troponin T (hs-TnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations, which both separately and in combination with echocardiographic variables, will be correlated to common risk factors, including COPD status. The PhD candidate has completed all mandatory courses at the University of Oslo and has submitted 2 manuscripts to international peer reviewed journals and 1 article is in revision. The third manuscript of the thesis will be finalized and submitted during Q2 2019. In these articles we have explored sensitive markers of left ventricular (LV) structure and function and cardiomyocyte injury and strain, and we find that a number of variables influence myocardial function. This is ongoing work, especially related to article 3, but current data indicate a modest influence by COPD status to indices of LV deformation. However, we will use a more comprehensive assessment of myocardial function in article 3 and therefore the conclusion of this project will be provided in the report for next year. Akershus University Hospital has granted extended funding for this project after external review as part of Strategic funding for research 2019.
2017
Patients with chronic obstructive pulmonary disease (COPD) often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors, but also to direct effects by COPD and other risk factors on the myocardium. We will utilize both sensitive echocardiographic and biological markers to explore this research question.Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we will utilize both sensitive echocardiographic indices and biological markers (biomarkers) to explore this research question more closely. We have already included the cohort of interest with pulmonary testing in all subjects, and we have recently also finalized the analyses of all the echocardiographic examinations. We have also completed measurements of high-sensitivity troponin I (hs-TnI) levels, which both separately and in combination with echocardiographic variables, will be correlated to common risk factors, including the severity of COPD as measured by symptoms and pulmonary testing. The PhD candidate has completed all mandatory courses at the University of Oslo and we have a manuscript almost ready (PhD candidate as the 1st author) and manuscript #2 currently being submitted (PhD candidate 2nd author). We will especially be interested in the effect of COPD, and other risk factors, on local deformation of the myocardium, and such novel echocardiographic indices will be compared with established markers of left ventricular function (measurements of dimension and structure, and ejection fraction). As hs-troponin levels seem to represent a sensitive marker of alterations in structure during the development of left ventricular remodeling, we will also explore the influence of COPD and other common risk factors on hs-TnI levels, and link this directly to echocardiographic evidence of myocardial dysfunction (manuscript #3). Accordingly, by both having access to hs-troponin measurements, data on pulmonary testing, sensitive echocardiographic indices, and patient medical data, this project should have potential to increase our knowledge regarding the influence of COPD and other risk factors on myocardial function. Given the increasing numbers of elderly subjects with comorbidities in the Norwegian population, this project should therefore be of relevance for large patient groups.
2016
Patients with chronic obstructive pulmonary disease (COPD) often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors, but also to direct effects by COPD and other risk factors on the myocardium. We will utilize both sensitive echocardiographic and biological markers to explore this research question.Patients with COPD often have comorbidities, including myocardial dysfunction. This may relate both to common risk factors; e.g. smoking, but also to direct effects by COPD and other risk factors on the myocardium. Accordingly, in this project we will utilize both sensitive echocardiographic indices and biological markers (biomarkers) to explore this research question more closely. We have already included the cohort of interest with pulmonary testing in all subjects, and we have recently also finalized the analyses of all the echocardiographic examinations. We have also completed measurements of high-sensitivity troponin I (hs-TnI) levels, which both separately and in combination with echocardiographic variables, will be correlated to common risk factors, including the severity of COPD as measured by symptoms and pulmonary testing. The PhD candidate has completed all mandatory courses at the University of Oslo and we have currently started drafting manuscripts #1 (PhD candidate as the 1st author) and #2 (2nd author) for the PhD thesis. We will especially be interested in the effect of COPD, and other risk factors, on local deformation of the myocardium, and such novel echocardiographic indices will be compared with established markers of left ventricular function (measurements of dimension and structure, and ejection fraction). As hs-troponin levels seem to represent a sensitive marker of alterations in structure during the development of left ventricular remodeling, we will also explore the influence of COPD and other common risk factors on hs-TnI levels, and link this directly to echocardiographic evidence of myocardial dysfunction. Accordingly, by both having access to hs-troponin measurements, data on pulmonary testing, sensitive echocardiographic indices, and patient medical data, this project should have potential to increase our knowledge regarding the influence of COPD and other risk factors on myocardial function. Given the increasing numbers of elderly subjects with comorbidities in the Norwegian population, this project should therefore be of relevance for large patient groups.
2015
Kronisk obstruktiv lungesykdom (KOLS) vil øke de neste årene. KOLS er assosiert med høy sykelighet og mortalitet. I dette prosjektet vil vi undersøke samspillet mellom nedsatt lungefunksjon og redusert hjertefunksjon vurdert ved ultralyd og blodprøver.Pasienter med KOLS har økt risiko for hjerte-karsykdom pga høy andel røyking og lavgradig systemisk inflammasjon. Betydningen av hjerte-karsykdom for sykelighet og død ved KOLS er godt dokumentert med hjerteskade og nedsatt hjertefunksjon anslått å bidra til 25% av alle dødsfall ved KOLS. Dette gjelder særlig under akutte forverringer av KOLS (akutt KOLS) med sykehusinnleggelse. Ved akutt KOLS øker nemlig belastningen på hjertet pga pustebesvær med påfølgende rask puls sekundært til stress-hormoner i blodet. Det aktuelle prosjektet vil undersøke bidraget fra nedsatt hjertefunksjon, målt med ultralydundersøkelser av hjertet (ekkokardiografi) og blodprøver, til sykelighet ved akutt og kronisk KOLS. Vi vil også undersøke om hjertemarkøren troponin T, målt med veldig sensitiv målemetode, kan identifisere KOLS-pasientene med nedsatt hjertefunksjon. Det er i dag ingen god metode for enkelt å identifisere disse pasientene og troponin T kan derfor potensielt få stor betydning for mer målrettet behandling av KOLS-pasienter med nedsatt hjertefunksjon. Prosjektet er vel i gang og PhD-kandidat Erika N. Aagaard har sammen med ansatte ved Akershus universitetssykehus og Bærum sykehus undersøkt 3700 deltagere i ACE 1950 Study med ultralyd og lungefunksjonsmåling (spirometri). Metodeartikkel fra ACE 1950 Study er publisert og vi vil starte dataanalyse i Q2 2016 når alle data fra ekkokardiografi er klar. Aagaard er også oppmeldt på PhD-programmet ved UiO og har tatt flere kurs der. Vi har også innledet er samarbeid med Dr. Jørgen Gravning og hans PhD-kandidat Brede A. Kvisvik, UiO, slik at de også vil bidra til pasientinklusjon i et komplementært prosjektet med akutt KOLS (ACE 4 Study). Godkjenning fra REK og Personvernombud på Akershus universitetssykehus er innvilget for ACE 4 Study og vi starter pasientinklusjon i Q3 2016.
2014
Kronisk obstruktiv lungesykdom (KOLS) vil øke de neste årene. KOLS er assosiert med høy sykelighet og mortalitet. I dette prosjektet vil vi undersøke hjertesykelighet hos KOLS-pasienter da nedsatt hjertefunksjon har vært assosiert med opp til 25% av alle dødsfall for KOLS.Pasienter med KOLS har økt risiko for hjerte-karsykdom pga høy andel røyking og lavgradig systemisk inflammasjon. Betydningen av hjerte-karsykdom for sykelighet og død ved KOLS er godt dokumentert med hjerteskade og nedsatt hjertefunksjon anslått å bidra til 25% av alle dødsfall ved KOLS. Dette gjelder særlig under akutte forverringer av KOLS (akutt KOLS) med sykehusinnleggelse. Ved akutt KOLS øker nemlig belastningen på hjertet pga pustebesvær med påfølgende rask puls sekundært til stress-hormoner i blodet. Det aktuelle prosjektet vil undersøke bidraget fra nedsatt hjertefunksjon, målt med gjentatte ultralydundersøkelser av hjertet (ekkokardiografi), til sykelighet ved akutt KOLS. Vi vil også undersøke om hjertemarkøren troponin T, målt med veldig sensitiv målemetode, kan identifisere KOLS-pasientene med nedsatt hjertefunksjon. Det er i dag ingen god metode for enkelt å identifisere disse pasientene og troponin T kan derfor potensielt få stor betydning for mer målrettet behandling av KOLS-pasienter med nedsatt hjertefunksjon. Prosjektet er vel i gang og PhD-kandidat Erika N. Aagaard har blitt ansatt. Prosjektet er svært utfordrende teknisk da det er vanskelig å få gode ekkokardiografiske bilder av hjertet hos pasienter med akutt KOLS. Aagaard har derfor jobbet mye med å bli dyktig innen ekkokardiografi og undersøker nå selvstendig i den store befolkningsstudien ACE 1950 Study (ClinicalTrials.gov Identifier: NCT01555411). Aagaard er oppmeldt på PhD-programmet ved UiO og har tatt kurs der. Hun jobber også med en artikkel utgått fra en tidligere studie, ACE 2, der hun vil se på procalcitonin ved akutt pustebesvær, noe som passer fint med hennes doktorgradsprosjekt. Det er ventet at hun publiserer en artikkel på dette i 2015. Vi har også innledet er samarbeid med Dr. Jørgen Gravning og hans PhD-kandidat Brede A. Kvisvik, UiO, slik at de også vil bidra til pasientinklusjon i prosjektet innenfor rammen av en større studie på pasienter med pustebesvær (ACE 4 Study). Protokoll for REK og Personvernombud på Akershus universitetssykehus er under utarbeidelse og vi vil starte pasientinklusjon i løp av de neste månedene.
Vitenskapelige artikler
Lyngbakken MN, Kvisvik B, Berge T, Pervez MO, Aagaard EN, Ariansen I, Omland T, Tveit A, Steine K, Røsjø H

Serial blood pressure measurements, left ventricular remodelling and cardiovascular outcomes.

Eur J Clin Invest 2023 Jan;53(1):e13876. Epub 2022 sep 24

PMID: 36120822

Lyngbakken MN, Rønningen PS, Solberg MG, Berge T, Brynildsen J, Aagaard EN, Kvisvik B, Røsjø H, Steine K, Tveit A, Omland T

Prediction of incident atrial fibrillation with cardiac biomarkers and left atrial volumes.

Heart 2023 Feb 14;109(5):356. Epub 2023 feb 14

PMID: 36261282

Aagaard EN, Lyngbakken MN, Kvisvik B, Berge T, Pervez MO, Ariansen I, Tveit A, Steine K, Røsjø H, Omland T

Associations between cardiovascular risk factors, biomarkers, and left ventricular mechanical dispersion: insights from the ACE 1950 Study.

Eur Heart J Open 2022 Mar;2(2):oeac006. Epub 2022 feb 12

PMID: 35919126 - Inngår i doktorgradsavhandlingen

Rønningen PS, Berge T, Solberg MG, Enger S, Pervez MO, Orstad EB, Kvisvik B, Aagaard EN, Lyngbakken MN, Ariansen I, Røsjø H, Steine K, Tveit A

Impact of Blood Pressure in the Early 40s on Left Atrial Volumes in the Mid-60s: Data From the ACE 1950 Study.

J Am Heart Assoc 2022 Jun 07;11(11):e023738. Epub 2022 mai 27

PMID: 35621203

Myhre PL, Lyngbakken MN, Berge T, Røysland R, Aagaard EN, Pervez O, Kvisvik B, Brynildsen J, Norseth J, Tveit A, Steine K, Omland T, Røsjø H

Diagnostic Thresholds for Pre-Diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population:

J Am Heart Assoc 2021 06;10(11):e020447. Epub 2021 mai 17

PMID: 33998259

Lyngbakken MN, Kvisvik B, Aagaard EN, Berge T, Pervez MO, Brynildsen J, Tveit A, Steine K, Røsjø H, Omland T

B-Type Natriuretic Peptide Is Associated with Indices of Left Ventricular Dysfunction in Healthy Subjects from the General Population: The Akershus Cardiac Examination 1950 Study.

Clin Chem 2021 01 08;67(1):204-215.

PMID: 33279958

Lyngbakken MN, Aagaard EN, Kvisvik B, Berge T, Pervez MO, Brynildsen J, Tveit A, Steine K, Røsjø H, Omland T

Cardiac Troponin I and T Are Associated with Left Ventricular Function and Structure: Data from the Akershus Cardiac Examination 1950 Study.

Clin Chem 2020 04 01;66(4):567-578.

PMID: 32227098

Rønningen PS, Berge T, Solberg MG, Enger S, Nygård S, Pervez MO, Orstad EB, Kvisvik B, Aagaard EN, Røsjø H, Tveit A, Steine K

Sex differences and higher upper normal limits for left atrial end-systolic volume in individuals in their mid-60s: data from the ACE 1950 Study.

Eur Heart J Cardiovasc Imaging 2020 05 01;21(5):501-507.

PMID: 32031593

Aagaard EN, Kvisvik B, Pervez MO, Lyngbakken MN, Berge T, Enger S, Orstad EB, Smith P, Omland T, Tveit A, Røsjø H, Steine K

Left ventricular mechanical dispersion in a general population: Data from the Akershus Cardiac Examination 1950 study.

Eur Heart J Cardiovasc Imaging 2020 02 01;21(2):183-190.

PMID: 31504360 - Inngår i doktorgradsavhandlingen

Kvisvik B, Aagaard EN, Mørkrid L, Røsjø H, Lyngbakken M, Smedsrud MK, Eek C, Bendz B, Haugaa KH, Edvardsen T, Gravning J

Mechanical dispersion as a marker of left ventricular dysfunction and prognosis in stable coronary artery disease.

Int J Cardiovasc Imaging 2019 Jul;35(7):1265-1275. Epub 2019 jun 5

PMID: 31165941 - Inngår i doktorgradsavhandlingen

Klaeboe LG, Haland Tf, Leren Is, Ter Bekke RMA, Brekke PH, Røsjø H, Omland T, Gullestad L, Aakhus S, Haugaa KH, Edvardsen T

Prognostic Value of Left Ventricular Deformation Parameters in Patients with Severe Aortic Stenosis: A Pilot Study of the Usefulness of Strain Echocardiography.

J Am Soc Echocardiogr 2017 Aug;30(8):727-735.e1. Epub 2017 jun 7

PMID: 28599826

Winther JA, Brynildsen J, Høiseth AD, Strand H, Følling I, Christensen G, Nygård S, Røsjø H, Omland T

Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study.

Respir Res 2017 Nov 03;18(1):184. Epub 2017 nov 3

PMID: 29100503

Berge T, Vigen T, Pervez MO, Ihle-Hansen H, Lyngbakken MN, Omland T, Smith P, Steine K, Røsjø H, Tveit A,

Heart and Brain Interactions--the Akershus Cardiac Examination (ACE) 1950 Study Design.

Scand Cardiovasc J 2015;49(6):308-15. Epub 2015 sep 12

PMID: 26364744

Røsjø Helge, Vaahersalo Jukka, Hagve Tor-Arne, Pettilä Ville, Kurola Jouni, Omland Torbjørn, FINNRESUSCI Laboratory Study Group

Prognostic value of high-sensitivity troponin T levels in patients with ventricular arrhythmias and out-of-hospital cardiac arrest: data from the prospective FINNRESUSCI study.

Crit Care 2014;18(6):605. Epub 2014 nov 8

PMID: 25490117

Omland T, Røsjø H, Giannitsis E, Agewall S

Troponins in heart failure.

Clin Chim Acta 2014 Aug 21. Epub 2014 aug 21

PMID: 25151947

Einvik Gunnar, Røsjø Helge, Randby Anna, Namtvedt Silje K, Hrubos-Strøm Harald, Brynildsen Jon, Somers Virend K, Omland Torbjørn

Severity of obstructive sleep apnea is associated with cardiac troponin I concentrations in a community-based sample: data from the Akershus Sleep Apnea Project.

Sleep 2014 Jun;37(6):1111-6, 1116A-1116B. Epub 2014 jun 1

PMID: 24882906

Doktorgrader
Erika Nerdrum Aagaard

Studies on Mechanical Dispersion by Strain Echocardiography

Disputert:
september 2023
Hovedveileder:
Helge Røsjø
Deltagere
  • Torbjørn Omland Forsker (annen finansiering)
  • Arnljot Tveit Forsker (annen finansiering)
  • Helge Røsjø Hovedveileder
  • Kjetil Steine Medveileder
  • Erika Nerdrum Aagaard Doktorgradsstipendiat (finansiert av denne bevilgning)
  • Jørgen A. Gravning Prosjektdeltaker
  • Brede Alexander Kvisvik Doktorgradsstipendiat (annen finansiering)
  • Gunnar Einvik Forsker (annen finansiering)
  • Mohammad Osman Pervez Prosjektdeltaker
  • Brede A. Kvisvik Doktorgradsstipendiat

eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT

Alle henvendelser rettes til eRapport

Personvern  -  Informasjonskapsler